Sanofi Adr (SNY)

Aug 11, 2025

Kymera Revenue Drops 55 Percent in Q2 - The Motley Fool

Aug 11, 2025

Aug 05, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Aug 05, 2025

Aug 05, 2025

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha

Aug 05, 2025

Jul 31, 2025

Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025

Jul 31, 2025

Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria

Jul 31, 2025

Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025

Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025

Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025

Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025

Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent

Jul 14, 2025

Jul 01, 2025

Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha

Jul 01, 2025

Jun 13, 2025

SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com

Jun 13, 2025

Jun 09, 2025

Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.

Jun 09, 2025

Jun 02, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 02, 2025

Jun 02, 2025

France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail

Jun 02, 2025

Jun 02, 2025

Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news

Jun 02, 2025

May 31, 2025

European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize

May 31, 2025

May 30, 2025

Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar

May 30, 2025

May 30, 2025

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily

May 30, 2025

May 30, 2025

Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news

May 30, 2025

May 30, 2025

Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news

May 30, 2025

May 30, 2025

Regeneron shares plunge after mixed COPD drug trial results | NASDAQ:REGN - Proactive financial news

May 30, 2025

May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025

May 29, 2025

Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva

May 29, 2025

May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025

May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025